BCAL Diagnostics (ASX:BDX) ROCE %: -119.60% (As of Dec. 2025)


What is BCAL Diagnostics ROCE %?

BCAL Diagnostics ASX:BDX +10.96% ROCE % is -119.60% as of Dec. 2025. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BCAL Diagnostics's annualized ROCE % for the quarter that ended in Dec. 2025 was -119.60%.

BCAL Diagnostics  (ASX:BDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BCAL Diagnostics ROCE % Related Terms

BCAL Diagnostics ROCE % Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics ROCE % Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
ROCE %
-42.79 -101.07 -80.95 -87.37

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -71.06 -94.93 -79.90 -76.75 -119.60

BCAL Diagnostics ROCE % Calculation

BCAL Diagnostics's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-7.195/( ( (12.266 - 2.596) + (9.909 - 3.108) )/ 2 )
=-7.195/( (9.67+6.801)/ 2 )
=-7.195/8.2355
=-87.37 %

BCAL Diagnostics's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-7.578/( ( (9.909 - 3.108) + (7.173 - 1.302) )/ 2 )
=-7.578/( ( 6.801 + 5.871 )/ 2 )
=-7.578/6.336
=-119.60 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -119.60% mean?
BCAL Diagnostics (ASX:BDX) has a ROCE % of -119.60% as of Dec. 2025.
Is BCAL Diagnostics' ROCE % too high?
BCAL Diagnostics' current ROCE % is -119.60%.
How does BCAL Diagnostics' ROCE % compare to TMO and DHR?
BCAL Diagnostics' ROCE % of -119.60% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. BCAL Diagnostics's current ROCE % is -119.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current ROCE % of -119.60%. The current ROCE % is -119.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current ROCE % is -119.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.